Profile data is unavailable for this security.
About the company
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
- Revenue in USD (TTM)597.40m
- Net income in USD-15.51m
- Incorporated2005
- Employees652.00
- LocationSupernus Pharmaceuticals Inc9715 Key West AvenueROCKVILLE 20850United StatesUSA
- Phone+1 (301) 838-2500
- Fax+1 (302) 636-5454
- Websitehttps://www.supernus.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vir Biotechnology Inc | 79.60m | -539.44m | 1.40bn | 587.00 | -- | 0.9016 | -- | 17.55 | -4.01 | -4.01 | 0.5916 | 11.39 | 0.0357 | -- | -- | 135,603.10 | -24.19 | -0.6081 | -27.80 | -0.7192 | 98.85 | -- | -677.69 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Pacira Biosciences Inc | 681.75m | 70.47m | 1.41bn | 711.00 | 23.41 | 1.58 | 9.74 | 2.07 | 1.30 | 1.30 | 12.11 | 19.18 | 0.4389 | 1.93 | 7.00 | 958,866.40 | 4.54 | 3.35 | 4.84 | 3.98 | 73.15 | 72.63 | 10.34 | 8.57 | 4.78 | 51.11 | 0.3684 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Soleno Therapeutics Inc | 0.00 | -52.03m | 1.46bn | 33.00 | -- | 9.78 | -- | -- | -2.68 | -2.68 | 0.00 | 4.30 | 0.00 | -- | -- | 0.00 | -55.24 | -53.90 | -62.26 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Xencor Inc | 162.18m | -133.36m | 1.47bn | 280.00 | -- | 2.39 | -- | 9.03 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Tilray Brands Inc | 743.25m | -351.95m | 1.49bn | 1.60k | -- | 0.4148 | -- | 2.00 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.121 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
| Belite Bio Inc (ADR) | 0.00 | -32.61m | 1.49bn | 20.00 | -- | 15.12 | -- | -- | -1.18 | -1.18 | 0.00 | 3.24 | 0.00 | -- | -- | 0.00 | -46.26 | -- | -46.26 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Supernus Pharmaceuticals Inc | 597.40m | -15.51m | 1.49bn | 652.00 | -- | 1.60 | 21.44 | 2.50 | -0.2843 | -0.2843 | 10.86 | 16.90 | 0.3859 | 0.922 | 4.10 | 916,259.20 | -1.00 | 4.95 | -1.51 | 6.41 | 87.17 | 88.61 | -2.60 | 12.84 | 1.49 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Morphic Holding Inc | 0.00 | -161.25m | 1.52bn | 124.00 | -- | 2.29 | -- | -- | -3.49 | -3.49 | 0.00 | 13.25 | 0.00 | -- | -- | 0.00 | -28.67 | -22.69 | -29.49 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
| Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 1.52bn | 284.00 | -- | -- | -- | 36.64 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| Ligand Pharmaceuticals Inc | 118.31m | 96.34m | 1.53bn | 58.00 | 16.25 | 1.89 | 11.56 | 12.91 | 5.23 | 5.23 | 6.52 | 45.00 | 0.1372 | 0.5475 | 4.11 | 2,039,879.00 | 11.17 | 12.32 | 11.98 | 12.99 | 91.82 | 81.65 | 81.43 | 80.32 | 19.51 | -- | 0.00 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 55.14m | -156.83m | 1.53bn | 154.00 | -- | 19.55 | -- | 27.80 | -1.86 | -1.86 | 0.6334 | 0.8157 | 0.3573 | -- | 4.80 | 358,058.40 | -101.63 | -40.21 | -172.85 | -47.99 | 95.71 | -- | -284.42 | -374.75 | 2.60 | -14.71 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Dynavax Technologies Corp | 236.15m | 9.22m | 1.57bn | 408.00 | 240.04 | 2.54 | 114.76 | 6.65 | 0.05 | 0.05 | 1.67 | 4.73 | 0.2414 | 0.7769 | 3.24 | 578,796.60 | 0.9427 | 4.16 | 1.02 | 5.71 | 80.34 | 64.83 | 3.91 | 9.19 | 14.10 | -- | 0.265 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Kura Oncology Inc | 0.00 | -168.09m | 1.57bn | 142.00 | -- | 3.11 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -254.02m | 1.58bn | 120.00 | -- | 3.72 | -- | -- | -2.44 | -2.44 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 1.59bn | 111.00 | -- | 3.71 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Edgewise Therapeutics Inc | 0.00 | -105.85m | 1.60bn | 92.00 | -- | 2.99 | -- | -- | -1.53 | -1.53 | 0.00 | 5.73 | 0.00 | -- | -- | 0.00 | -23.52 | -- | -24.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Supernus Pharmaceuticals Inc's reporting currency: US Dollar USD
58.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 8.61m | 15.73% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 6.06m | 11.08% |
| Armistice Capital LLCas of 31 Mar 2024 | 3.57m | 6.53% |
| Macquarie Investment Management Business Trustas of 31 Mar 2024 | 2.67m | 4.88% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 2.56m | 4.67% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.04m | 3.73% |
| Polar Capital LLPas of 31 Mar 2024 | 1.94m | 3.55% |
| Stephens Investment Management Group LLCas of 31 Mar 2024 | 1.90m | 3.48% |
| Loomis, Sayles & Co. LPas of 31 Mar 2024 | 1.60m | 2.92% |
| GW&K Investment Management LLCas of 31 Mar 2024 | 1.34m | 2.45% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
